This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Baricitinib
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict SKIP-FOR-NOW HIGH
Effective for adult severe alopecia areata (BRAVE-AA1/AA2 Phase 3 — ~35-40% achieved 80%+ scalp coverage at 36 weeks at 4 mg/day). Not for MPB. Boxed warnings + cost mean it's only used for the AA indication. For Dylan with no AA diagnosis, no current indication. Mention here because the user asked about hair-loss adjacent compounds; baricitinib is the more potent JAK inhibitor in the AA space, vs ritlecitinib's slightly cleaner JAK3-selective profile.
▸ Verdict change log
- 2026-06-05 — Initial verdict SKIP-FOR-NOW. AA-only indication. (stub)
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.